サマリー

Anti-Parkinson Drugs are drugs used to treat Parkinson's disease.
The most commonly used Anti-Parkinson Drugs act on the dopaminergic system of the striatum and basal ganglia, or are central muscarinic antagonists.

Market Analysis and Insights: Global Anti-Parkinson Drugs Market
The global Anti-Parkinson Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Anti-Parkinson Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Anti-Parkinson Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Anti-Parkinson Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Anti-Parkinson Drugs market.

Global Anti-Parkinson Drugs Scope and Market Size
Anti-Parkinson Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Parkinson Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Dopaminergic
Dopamine Agonists
Enzyme Inhibitors
Others

Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Stores

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
Mylan Laboratories
Valeant Pharmaceuticals
Novartis
GlaxoSmithKline
Zambon Pharmaceuticals
Pfizer, Inc.
Hoffmann-La Roche
Merck & Co.
Orion Pharma
UCB
Teva Pharmaceutical Industries Ltd.
Vertical Pharmaceuticals, LLC
ACADIA Pharmaceuticals Inc.

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Dopaminergic
1.2.3 Dopamine Agonists
1.2.4 Enzyme Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Anti-Parkinson Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Stores
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Anti-Parkinson Drugs Market Perspective (2016-2027)
2.2 Anti-Parkinson Drugs Growth Trends by Regions
2.2.1 Anti-Parkinson Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Anti-Parkinson Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Anti-Parkinson Drugs Industry Dynamic
2.3.1 Anti-Parkinson Drugs Market Trends
2.3.2 Anti-Parkinson Drugs Market Drivers
2.3.3 Anti-Parkinson Drugs Market Challenges
2.3.4 Anti-Parkinson Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Anti-Parkinson Drugs Players by Revenue
3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2016-2021)
3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Anti-Parkinson Drugs Revenue
3.4 Global Anti-Parkinson Drugs Market Concentration Ratio
3.4.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2020
3.5 Anti-Parkinson Drugs Key Players Head office and Area Served
3.6 Key Players Anti-Parkinson Drugs Product Solution and Service
3.7 Date of Enter into Anti-Parkinson Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Anti-Parkinson Drugs Breakdown Data by Type
4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2016-2021)
4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2022-2027)

5 Anti-Parkinson Drugs Breakdown Data by Application
5.1 Global Anti-Parkinson Drugs Historic Market Size by Application (2016-2021)
5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Anti-Parkinson Drugs Market Size (2016-2027)
6.2 North America Anti-Parkinson Drugs Market Size by Type
6.2.1 North America Anti-Parkinson Drugs Market Size by Type (2016-2021)
6.2.2 North America Anti-Parkinson Drugs Market Size by Type (2022-2027)
6.2.3 North America Anti-Parkinson Drugs Market Size by Type (2016-2027)
6.3 North America Anti-Parkinson Drugs Market Size by Application
6.3.1 North America Anti-Parkinson Drugs Market Size by Application (2016-2021)
6.3.2 North America Anti-Parkinson Drugs Market Size by Application (2022-2027)
6.3.3 North America Anti-Parkinson Drugs Market Size by Application (2016-2027)
6.4 North America Anti-Parkinson Drugs Market Size by Country
6.4.1 North America Anti-Parkinson Drugs Market Size by Country (2016-2021)
6.4.2 North America Anti-Parkinson Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Anti-Parkinson Drugs Market Size (2016-2027)
7.2 Europe Anti-Parkinson Drugs Market Size by Type
7.2.1 Europe Anti-Parkinson Drugs Market Size by Type (2016-2021)
7.2.2 Europe Anti-Parkinson Drugs Market Size by Type (2022-2027)
7.2.3 Europe Anti-Parkinson Drugs Market Size by Type (2016-2027)
7.3 Europe Anti-Parkinson Drugs Market Size by Application
7.3.1 Europe Anti-Parkinson Drugs Market Size by Application (2016-2021)
7.3.2 Europe Anti-Parkinson Drugs Market Size by Application (2022-2027)
7.3.3 Europe Anti-Parkinson Drugs Market Size by Application (2016-2027)
7.4 Europe Anti-Parkinson Drugs Market Size by Country
7.4.1 Europe Anti-Parkinson Drugs Market Size by Country (2016-2021)
7.4.2 Europe Anti-Parkinson Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Anti-Parkinson Drugs Market Size (2016-2027)
8.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Type
8.2.1 Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Application
8.3.1 Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Anti-Parkinson Drugs Market Size by Region
8.4.1 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Anti-Parkinson Drugs Market Size (2016-2027)
9.2 Latin America Anti-Parkinson Drugs Market Size by Type
9.2.1 Latin America Anti-Parkinson Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Anti-Parkinson Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Anti-Parkinson Drugs Market Size by Type (2016-2027)
9.3 Latin America Anti-Parkinson Drugs Market Size by Application
9.3.1 Latin America Anti-Parkinson Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Anti-Parkinson Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Anti-Parkinson Drugs Market Size by Application (2016-2027)
9.4 Latin America Anti-Parkinson Drugs Market Size by Country
9.4.1 Latin America Anti-Parkinson Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Anti-Parkinson Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Anti-Parkinson Drugs Market Size (2016-2027)
10.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Type
10.2.1 Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Application
10.3.1 Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Anti-Parkinson Drugs Market Size by Country
10.4.1 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Anti-Parkinson Drugs Introduction
11.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 Mylan Laboratories
11.2.1 Mylan Laboratories Company Details
11.2.2 Mylan Laboratories Business Overview
11.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction
11.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.2.5 Mylan Laboratories Recent Development
11.3 Valeant Pharmaceuticals
11.3.1 Valeant Pharmaceuticals Company Details
11.3.2 Valeant Pharmaceuticals Business Overview
11.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction
11.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.3.5 Valeant Pharmaceuticals Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Anti-Parkinson Drugs Introduction
11.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.5.5 GlaxoSmithKline Recent Development
11.6 Zambon Pharmaceuticals
11.6.1 Zambon Pharmaceuticals Company Details
11.6.2 Zambon Pharmaceuticals Business Overview
11.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction
11.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.6.5 Zambon Pharmaceuticals Recent Development
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Company Details
11.7.2 Pfizer, Inc. Business Overview
11.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction
11.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.7.5 Pfizer, Inc. Recent Development
11.8 Hoffmann-La Roche
11.8.1 Hoffmann-La Roche Company Details
11.8.2 Hoffmann-La Roche Business Overview
11.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction
11.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.8.5 Hoffmann-La Roche Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Details
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Anti-Parkinson Drugs Introduction
11.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.9.5 Merck & Co. Recent Development
11.10 Orion Pharma
11.10.1 Orion Pharma Company Details
11.10.2 Orion Pharma Business Overview
11.10.3 Orion Pharma Anti-Parkinson Drugs Introduction
11.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.10.5 Orion Pharma Recent Development
11.11 UCB
11.11.1 UCB Company Details
11.11.2 UCB Business Overview
11.11.3 UCB Anti-Parkinson Drugs Introduction
11.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.11.5 UCB Recent Development
11.12 Teva Pharmaceutical Industries Ltd.
11.12.1 Teva Pharmaceutical Industries Ltd. Company Details
11.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction
11.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.12.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.13 Vertical Pharmaceuticals, LLC
11.13.1 Vertical Pharmaceuticals, LLC Company Details
11.13.2 Vertical Pharmaceuticals, LLC Business Overview
11.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction
11.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.13.5 Vertical Pharmaceuticals, LLC Recent Development
11.14 ACADIA Pharmaceuticals Inc.
11.14.1 ACADIA Pharmaceuticals Inc. Company Details
11.14.2 ACADIA Pharmaceuticals Inc. Business Overview
11.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction
11.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.14.5 ACADIA Pharmaceuticals Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details